Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1693785 | 0.74 | AXL (0.42) | EPHB3MAPTGAA | |
| SCHEMBL84318 | 0.74 | EPHB3 (0.37) | EPHB3MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL21863673 | 0.74 | EPHB3 (0.40) | EPHB3 | |
| SCHEMBL31276679 | 0.74 | EPHB3 (0.38) | EPHB3 | |
| SCHEMBL27077104 | 0.74 | EPHB3 (0.38) | EPHB3MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12067334 | 0.71 | EPHB3 (0.45) | EPHB3KDM4EALDH1A1HTTHSD17B10 | |
| SCHEMBL1693953 | 0.71 | CDK2 (0.49) | EPHB3KDM4EALDH1A1HTT | |
| SCHEMBL6842155 | 0.69 | EPHB3 (0.35) | EPHB3 | |
| SCHEMBL12453348 | 0.69 | EPHB3 (0.35) | EPHB3 | |
| SCHEMBL12522852 | 0.69 | EPHB3 (0.38) | EPHB3MAPTKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-117015536-A | 2- (indazol-5-yl) -6- (piperidin-4-yl) -1, 7-naphthyridine derivatives and related compounds as modulators of nucleic acid splicing and treatment of proliferative diseases | 雷密克斯医疗公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-7306631-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, JUP | EPHB3 2708/4885MAPT 874/4885KDM4E 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.